CCX507
/ Amgen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 13, 2014
ChemoCentryx's CEO discusses Q4 2013 results - Earnings call transcript
(SeekingAlpha)
- "Our goal is to seek a partner for vercirnon, possibly along with our second generation CCR9 inhibitor CCX507 in the treatment of inflammatory bowel disease..."; Anticipated completion of CCX507 P1 program in H1 2014.
Anticipated licensing / partnership • Anticipated trial completion date • Immunology • Inflammatory Bowel Disease
1 to 1
Of
1
Go to page
1